KRAS and gastric cancer: Although colorectal tumours with an activating mutation of the Kirsten(K)-ras gene are not sensitive to EGFR antibodies (Amado et al, 2008; Karapetis et al, 2008), the incidence of KRAS mutations in gastric cancer appears to be low (Kim et al, 2003; Lee et al, 2003; Zhao et al, 2004).